Every round on record, with the sources behind each and the investors on them.
Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source provides a Basel dateline, not a sentence stating headquarters; Kelun-Biotech and Harbour BioMed are named as licensing partners, not investors.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-01-10 | Blue Owl Healthcare Opportunities, Novo Holdings, OrbiMed | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source
The source provides a Basel dateline, not a sentence stating headquarters; Kelun-Biotech and Harbour BioMed are named as licensing partners, not investors. | ||||